- Author:
Sheng YANG
1
;
Xiaohui HE
;
Peng LIU
;
Shengyu ZHOU
;
Mei DONG
;
Yan QIN
;
Jianliang YANG
;
Changgong ZHANG
;
Xiaohong HAN
;
Yuankai SHI
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; adverse effects; Cross-Over Studies; Filgrastim; adverse effects; therapeutic use; Hematologic Agents; adverse effects; therapeutic use; Humans; Induction Chemotherapy; Injections, Subcutaneous; Multivariate Analysis; Neoplasms; drug therapy; Neutropenia; chemically induced; prevention & control; Time Factors
- From: Chinese Journal of Oncology 2016;38(1):69-72
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the duration of preventive filgrastim administration as support for chemotherapy and its affecting factors.
METHODSSingle institutional data from a phase Ⅱ clinical trial and a phase Ⅲ clinical trial of pegylated filgrastim were combined. In the two randomized cross-over trials, patients with previously untreated cancer received two cycles of chemotherapy of the same regimen. In the study group, the patients received a single subcutaneous injection of 100 μg/kg pegylated filgrastim, and in the control group, they received daily subcutaneous injections of 5 μg/kg filgrastim.
RESULTSIn 53 chemotherapy cycles, the median duration of filgrastim administration was (9.57±2.10)d. 83.0% (44/53) of them received filgrastim for 7-11 days. Patients with baseline absolute neutrophil count of <4×10(9)/L or body mass index less than 22 received a longer filgrastim prophylaxis(P<0.05). RESULTS of multivariate analysis showed that the baseline absolute neutrophil count is associated with the time of filgrastim administration(P=0.019). The most common adverse event of rhG-CSF was skeletal pain, generally mild and no treatment-related death occurred.
CONCLUSIONSThe median duration of filgrastim support for chemotherapy was 10 days. Patients with lower baseline neutrophil count require a longer filgrastim prophylaxis.
TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01285219.